Baseline characteristics
| . | Rituximab (n = 33) . | Placebo (n = 27) . |
|---|---|---|
| Females, N (%) | 19 (57.6) | 16 (59.3) |
| Age, median (IQR) | 40 (30-59) | 40 (31-59) |
| ITP stage, N (%) | ||
| Newly diagnosed | 17 (51.5) | 11 (40.7) |
| Relapsed | 16 (48.5) | 16 (59.3) |
| Duration of ITP, mo (median, IQR) | 3 (1-47) | 8 (1-40) |
| Baseline platelet count, × 109/L (median, IQR) | 15 (4-23) | 14 (10-23) |
| Standard treatments, N (%) | ||
| Prednisone | 18 (54.5) | 17 (63.0) |
| Dexamethasone | 13 (39.4) | 8 (29.6) |
| IVIg | 13 (39.4) | 9 (33.3) |
| Rhesus Ig | 2 (6.1) | 1 (3.7) |
| Solumedrol | 2 (6.1) | 0 |
| Methylprednisolone | 2 (6.1) | 0 |
| Romiplostim | 0 | 1 (3.7) |
| Platelet transfusions | 1 (3.0) | 0 |
| Combination | 11 (33.3) | 7 (25.9) |
| Evaluation period, days* (median, IQR) | 138 (130-144) | 137 (114-142) |
| . | Rituximab (n = 33) . | Placebo (n = 27) . |
|---|---|---|
| Females, N (%) | 19 (57.6) | 16 (59.3) |
| Age, median (IQR) | 40 (30-59) | 40 (31-59) |
| ITP stage, N (%) | ||
| Newly diagnosed | 17 (51.5) | 11 (40.7) |
| Relapsed | 16 (48.5) | 16 (59.3) |
| Duration of ITP, mo (median, IQR) | 3 (1-47) | 8 (1-40) |
| Baseline platelet count, × 109/L (median, IQR) | 15 (4-23) | 14 (10-23) |
| Standard treatments, N (%) | ||
| Prednisone | 18 (54.5) | 17 (63.0) |
| Dexamethasone | 13 (39.4) | 8 (29.6) |
| IVIg | 13 (39.4) | 9 (33.3) |
| Rhesus Ig | 2 (6.1) | 1 (3.7) |
| Solumedrol | 2 (6.1) | 0 |
| Methylprednisolone | 2 (6.1) | 0 |
| Romiplostim | 0 | 1 (3.7) |
| Platelet transfusions | 1 (3.0) | 0 |
| Combination | 11 (33.3) | 7 (25.9) |
| Evaluation period, days* (median, IQR) | 138 (130-144) | 137 (114-142) |
IQR indicates interquartile range.
Evaluation period was from the completion of standard treatment (8 weeks from the start of standard treatment) until the end of follow-up (6 months from randomization).